Rande, Regulars, Newbies, & Lurkers.....
VASO...had a very substantial PR after hours with an *endorsement* from the MAYO Clinic for their heart disease process......for all that read this.....a little lesson from one who has left, yet again, a ton of cash on the table.....VASO has been a trading stock for me, for the last 3 months....nice story, beautiful T/A, forming a nice double pennant....but alas this is a stock in which I did not apply Rande's investment/trading strategy....I failed to develop a *core* holding around my trading basis of shares...I continually traded the entire block...quite successfully I might add...however, and here is the important point in this, I was caught on the wrong side this time....I traded out of VASO last Friday...and do not have a *core* holding...and you can see what has happened....so even if I add up all my scalps/profits from the many, many times I've traded VASO they would pale in comparison to where this is FINALLY going....
Lesson here, for me anyways, Rande's core/trading philosophy has proven to be sound....and one that I learned to late with VASO....
Proud to say that I have adopted this process for a few *others*, CICI being the biggest & will continue to trade/invest this way in the future....So once again, Rande, you are not wasting your time here on this thread....thanks <steven>
PS>>>>VASO PR -------->
Mayo Clinic Physicians Confirm Positive Early Results With Enhanced External Counterpulsation
WESTBURY, NY--(BUSINESS WIRE)--Feb. 29, 2000--Vasomedical, Inc. (Nasdaq: VASO) announced today
that the Mayo Clinic, one of the most respected medical facilities in the world, has reported further on initial results
with enhanced external counterpulsation (EECP(R)) therapy. Their positive experience was recently published as an
interview in the Rochester Post-Bulletin and confirms several case studies reported at the AHA in November.
Gregory Barsness, M.D., Medical Director for the EECP therapy program at Mayo reported, "Of the 21 patients
who've tried the therapy since Mayo started using it a year ago, 20 of them have had positive results, some have
improved dramatically. We are cautiously optimistic about the therapy, ...we have had dramatic responses, so we're
enthusiastic and we're actively pursuing it."
EECP therapy is a noninvasive outpatient treatment for the angina (chest pain) which often accompanies coronary
artery disease. The therapy, which is covered by Medicare, is relatively new to the Mayo Clinic, but is in use at over
100 centers across the country.
Dr. Barsness further indicated that Mayo and other medical centers are studying EECP therapy to determine why
the treatment works in so many patients. He pointed out that heart disease is a leading killer of both men and
women; many heart disease patients do not qualify for common treatment methods and EECP therapy could turn
out to be a big help for these patients.
Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting external
counterpulsation systems based on the company's proprietary technology. EECP(R) is a registered trademark for
Vasomedical's enhanced external counterpulsation system. This system is now in use at major medical centers,
including the Mayo Clinic, the Ochsner Foundation Hospital and the Miami Heart Institute, as well as medical
centers affiliated with Columbia University, the University of Pittsburgh, the University of California San Diego, the
University of California San Francisco, and the University of Virginia. The company provides hospitals, clinics and
private practices EECP(R) equipment, treatment guidance and a staff training and maintenance program to ensure
optimal patient outcomes.
Except for historical information contained in this release, the matters discussed are forward looking statements that
involve risks and uncertainties. When used in this release, words such as "anticipate," "believe," "estimate," "expect"
and "intend" and similar expressions, as they relate to the Company or its management, identify forward-looking
statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as
assumptions made by and information currently available to the Company's management. Among the factors that
could cause actual results to differ materially are the following: the effect of business and economic conditions; the
impact of competitive products and pricing; capacity and supply constraints or difficulties; product development,
commercialization or technological difficulties; the regulatory and trade environment; and the risk factors reported
from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any
forward-looking statements as a result of future events or developments.
--------------------------------------------------------------------------------
Contact:
Anthony Peacock
VP Clinical Affairs
516/997-4600 Ext. 120
or
Jeanette Hutter
MediaMedica, Inc.
215/402-9175
eecp.com/news |
